Novartis AG ADR (NVS)vsOption Care Health Inc (OPCH)
NVS
Novartis AG ADR
$158.83
-0.25%
HEALTHCARE · Cap: $290.96B
OPCH
Option Care Health Inc
$22.46
-6.14%
HEALTHCARE · Cap: $3.41B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 900% more annual revenue ($56.69B vs $5.67B). NVS leads profitability with a 22.5% profit margin vs 3.6%. OPCH appears more attractively valued with a PEG of 1.22. OPCH earns a higher WallStSmart Score of 56/100 (C).
NVS
Buy51
out of 100
Grade: C-
OPCH
Buy56
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-70.9%
Fair Value
$92.73
Current Price
$158.83
$66.10 premium
Margin of Safety
-4.8%
Fair Value
$33.09
Current Price
$22.46
$10.63 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 31.8%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Attractively priced relative to earnings
Reasonable price relative to book value
Areas to Watch
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
1.3% revenue growth
3.4% earnings growth
3.6% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 31.8%.
Bull Case : OPCH
The strongest argument for OPCH centers on P/E Ratio, Price/Book. PEG of 1.22 suggests the stock is reasonably priced for its growth.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Bear Case : OPCH
The primary concerns for OPCH are Revenue Growth, EPS Growth, Profit Margin. Thin 3.6% margins leave little buffer for downturns.
Key Dynamics to Monitor
OPCH carries more volatility with a beta of 0.65 — expect wider price swings.
OPCH is growing revenue faster at 1.3% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
OPCH scores higher overall (56/100 vs 51/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Option Care Health Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Option Care Health, Inc. offers infusion services at home and at alternative sites in the United States. The company is headquartered in Bannockburn, Illinois.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?